Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093029 | 0.95 | PPARA (0.58) | PPARACACNA1BKLK7KLK5CTSS | |
| SCHEMBL3004720 | 0.95 | PPARA (0.58) | PPARACACNA1BKLK7KLK5CTSS | |
| SCHEMBL5033775 | 0.95 | PPARA (0.58) | PPARACACNA1BKLK7KLK5CTSS | |
| SCHEMBL14211452 | 0.89 | PPARA (0.57) | PPARACACNA1BKLK7KLK5CTSS | |
| SCHEMBL18256446 | 0.87 | PPARA (0.55) | PPARACACNA1BKLK7KLK5CTSS | |
| SCHEMBL4370045 | 0.86 | KLK5 (0.65) | PPARACACNA1BKLK7KLK5CTSS | |
| SCHEMBL16286010 | 0.85 | CACNA1B (0.59) | PPARACACNA1BKLK7KLK5CTSS | |
| SCHEMBL20144655 | 0.85 | CACNA1B (0.59) | PPARACACNA1BKLK7KLK5CTSS | |
| SCHEMBL20481004 | 0.85 | CACNA1B (0.59) | PPARACACNA1BKLK7KLK5CTSS | |
| SCHEMBL7965696 | 0.85 | PPARA (0.56) | PPARACACNA1BKLK7KLK5CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160143985-A1 | ICE-CLEAVED ALPHA-SYNUCLEIN AS A BIOMARKER | BRANDEIS UNIVERSITY (US) | 2016-05-26 | — | — | US | disclosed |
| US-9116157-B2 | Ice-cleaved alpha-synuclein as a biomarker | BRANDEIS UNIVERSITY (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140309172-A1 | ICE INHIBITING COMPOUNDS AND USES THEREOF | BRANDEIS UNIVERSITY | 2014-10-16 | — | — | US | disclosed |
| US-20130316384-A1 | ICE-CLEAVED ALPHA-SYNUCLEIN AS A BIOMARKER | BRANDEIS UNIVERSITY | 2013-11-28 | — | — | US | disclosed |
| EP-2635907-A1 | ICE CLEAVED ALPHA-SYNUCLEIN A BIOMARKER | BRANDEIS UNIVERSITY (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2635906-A2 | ICE INHIBITING COMPOUNDS AND USES THEREOF | BRANDEIS UNIVERSITY (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061786-A1 | ICE CLEAVED ALPHA-SYNUCLEIN A BIOMARKER | BRANDEIS UNIVERSITY (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061785-A2 | ICE INHIBITING COMPOUNDS AND USES THEREOF | BRANDEIS UNIVERSITY (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20110082096-A1 | GENE AND PATHWAY AND THEIR USE IN METHODS AND COMPOSITIONS FOR PREDICTING ONSET OR PROGRESSION OF AUTOIMMUNE AND/OR AUTOINFLAMMATORY DISEASES | NIH - DIETR | 2011-04-07 | — | — | US | disclosed |
| US-20090298764-A1 | GENE AND PATHWAY AND THEIR USE IN METHODS AND COMPOSITIONS FOR PREDICTING ONSET OR PROGRESSION OF AUTOIMMUNE AND/OR AUTOINFLAMMATORY DISEASES | REGENTS OF THE UNIVERSITY OF COLORADO | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143985-A1 | ICE-CLEAVED ALPHA-SYNUCLEIN AS A BIOMARKER | SNCA, BACE2, PYGB | PPARA 3997/4885CACNA1B 2283/4885KLK7 3174/4885 |
| US-20110082096-A1 | GENE AND PATHWAY AND THEIR USE IN METHODS AND COMPOSITIONS FOR PREDICTING ONSET OR PROGRESSION OF AUTOIMMUNE AND/OR AUTOINFLAMMATORY DISEASES | NLRP1, PYCARD, NLRP3 | PPARA 2544/4885CACNA1B 371/4885KLK7 2777/4885 |
| US-20140309172-A1 | ICE INHIBITING COMPOUNDS AND USES THEREOF | CASP1, AIFM1, CASP2 | PPARA 3411/4885CACNA1B 768/4885KLK7 4303/4885 |
| US-20090298764-A1 | GENE AND PATHWAY AND THEIR USE IN METHODS AND COMPOSITIONS FOR PREDICTING ONSET OR PROGRESSION OF AUTOIMMUNE AND/OR AUTOINFLAMMATORY DISEASES | NLRP1, PYCARD, NLRP3 | PPARA 2544/4885CACNA1B 371/4885KLK7 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.